Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction

ReachMD Healthcare Image
Media formats available:
Details
Presenters
  • Overview

    Join Drs. Scott Solomon and John McMurray as they examine the new indication for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in treating patients with heart failure with LVEF ≥40%. Drawing on data from the FINEARTS-HF trial, faculty discuss patient selection, dosing considerations based on renal function, and the additive benefits of combining finerenone with SGLT2 inhibitors. A clinical case illustrates typical comorbidities—atrial fibrillation, hypertension, and diabetes—and how finerenone may address multiple cardiovascular and metabolic risks.  

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer AG. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, it is the policy of MEDCON International that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. MEDCON International has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity. 

    The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.

    Faculty: 
    John McMurray, MD

    Professor of Medical Cardiology
    University of Glasgow
    Glasgow, UK

    Clinical trials and grants: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, British Heart Foundation, Cardurion, Catalyze Group, Cytokinetics, GSK/Novartis, National Institute for Health/National Heart Lung and Blood Institute (NIH/NHLBI), SQ Innovations 
    Consulting: Alnylam Pharmaceuticals, Amgen, AnaCardio, AstraZeneca, Bayer, Berlin Cures, BMS, Cardurion, Cytokinetics, Ionis Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, River 2 Renal Corp
    Lecture fees: Abbott, Alkem Metabolics, AstraZeneca, Blue Ocean Scientific Solutions Ltd., Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharmaceuticals Ltd., Eris Lifesciences, European Academy of CME, Hikma Pharmaceuticals, Imagica Health, Intas Pharmaceuticals, JB Chemicals & Pharmaceuticals Ltd., Lupin Pharmaceuticals, Medscape/Heart.org, ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, The Corpus, Translation Research Group, Translational Medicine Academy
    Data Safety Monitoring Board: WIRB-Copernicus Group Clinical Inc. 
    Director of Global Clinical Trial Partners Ltd.

    Scott Solomon, MD
    The Edward D. Frolich Distinguished Chair
    Brigham and Women’s Hospital
    Harvard University 
    Boston, MA

    Consulting: Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, DiNAQOR, GSK, Lilly, Novartis, Quantum Genomics, Roche, Sanofi Pasteur, Tenaya, Theracos, Tremeau
    Research: Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly, NIH/NHLBI, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, Us2.ai

    Reviewers/Content Planners/Authors: 
     

    • Cindy Davidson has no relevant relationships to disclose.  
    • Kathleen Sheridan, PhD, has no relevant relationships to disclose.  
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.  

     

  • Learning Objectives

    Upon completion of this activity, learners should be better able to: 

    • Select patients with heart failure who are most likely to benefit from nonsteroidal mineralocorticoid receptor antagonist therapy 
    • Design evidence-based treatment plans to optimize outcomes in patients with heart failure with preserved ejection fraction or (heart failure with mid-range ejection fraction 
  • Target Audience

    This activity has been designed to meet the educational needs of cardiologists and nephrologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with heart failure. 

  • Accreditation and Credit Designation Statements

    This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®). Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association physicians may convert EBAC® CE credits toAMA PRA Category 1 Credits. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™. 

    This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®for 15 minutes of effective education time. 

  • Provider(s)/Educational Partner(s)

    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MEDCON International. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. 

    Reproduction Prohibited 

    Reproduction of this material is not permitted without written permission from the copyright owner.  

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying PACE-CME…
but how about a more personalized experience?

Register for free